[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse STAT1

Summary
SymbolSTAT1
Namesignal transducer and activator of transcription 1, 91kDa
Aliases STAT91; transcription factor ISGF-3 components p91/p84; signal transducer and activator of transcription 1, ......
Chromosomal Location2q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Translocated into the nucleus upon tyrosine phosphorylation and dimerization, in response to IFN-gamma and signaling by activated FGFR1, FGFR2, FGFR3 or FGFR4 (PubMed:15322115). Monomethylation at Lys-525 is required for phosphorylation at Tyr-701 and translocation into the nucleus (PubMed:28753426). Translocates into the nucleus in response to interferon-beta stimulation (PubMed:26479788).
Domain PF00017 SH2 domain
PF12162 STAT1 TAZ2 binding domain
PF01017 STAT protein
PF02864 STAT protein
PF02865 STAT protein
Function

Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors. Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signaling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus (PubMed:28753426). ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of IFN-stimulated genes (ISG), which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated (PubMed:26479788). It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state. Becomes activated in response to KITLG/SCF and KIT signaling. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001525 angiogenesis
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001822 kidney development
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001937 negative regulation of endothelial cell proliferation
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0002053 positive regulation of mesenchymal cell proliferation
GO:0003013 circulatory system process
GO:0003337 mesenchymal to epithelial transition involved in metanephros morphogenesis
GO:0003338 metanephros morphogenesis
GO:0003339 regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis
GO:0003340 negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis
GO:0006979 response to oxidative stress
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007259 JAK-STAT cascade
GO:0007584 response to nutrient
GO:0008015 blood circulation
GO:0009612 response to mechanical stimulus
GO:0009615 response to virus
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010463 mesenchymal cell proliferation
GO:0010464 regulation of mesenchymal cell proliferation
GO:0010742 macrophage derived foam cell differentiation
GO:0014074 response to purine-containing compound
GO:0016525 negative regulation of angiogenesis
GO:0030856 regulation of epithelial cell differentiation
GO:0030857 negative regulation of epithelial cell differentiation
GO:0031667 response to nutrient levels
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0033002 muscle cell proliferation
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034340 response to type I interferon
GO:0034341 response to interferon-gamma
GO:0034612 response to tumor necrosis factor
GO:0035456 response to interferon-beta
GO:0035458 cellular response to interferon-beta
GO:0035850 epithelial cell differentiation involved in kidney development
GO:0042493 response to drug
GO:0042542 response to hydrogen peroxide
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043434 response to peptide hormone
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0045088 regulation of innate immune response
GO:0045765 regulation of angiogenesis
GO:0046683 response to organophosphorus
GO:0046719 regulation by virus of viral protein levels in host cell
GO:0046725 negative regulation by virus of viral protein levels in host cell
GO:0048514 blood vessel morphogenesis
GO:0048525 negative regulation of viral process
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048762 mesenchymal cell differentiation
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0050792 regulation of viral process
GO:0051591 response to cAMP
GO:0051607 defense response to virus
GO:0060231 mesenchymal to epithelial transition
GO:0060330 regulation of response to interferon-gamma
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0060334 regulation of interferon-gamma-mediated signaling pathway
GO:0060337 type I interferon signaling pathway
GO:0060338 regulation of type I interferon-mediated signaling pathway
GO:0060485 mesenchyme development
GO:0060759 regulation of response to cytokine stimulus
GO:0060993 kidney morphogenesis
GO:0061005 cell differentiation involved in kidney development
GO:0061326 renal tubule development
GO:0071346 cellular response to interferon-gamma
GO:0071356 cellular response to tumor necrosis factor
GO:0071357 cellular response to type I interferon
GO:0071375 cellular response to peptide hormone stimulus
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072028 nephron morphogenesis
GO:0072073 kidney epithelium development
GO:0072074 kidney mesenchyme development
GO:0072075 metanephric mesenchyme development
GO:0072077 renal vesicle morphogenesis
GO:0072080 nephron tubule development
GO:0072087 renal vesicle development
GO:0072088 nephron epithelium morphogenesis
GO:0072111 cell proliferation involved in kidney development
GO:0072135 kidney mesenchymal cell proliferation
GO:0072136 metanephric mesenchymal cell proliferation involved in metanephros development
GO:0072160 nephron tubule epithelial cell differentiation
GO:0072161 mesenchymal cell differentiation involved in kidney development
GO:0072162 metanephric mesenchymal cell differentiation
GO:0072170 metanephric tubule development
GO:0072182 regulation of nephron tubule epithelial cell differentiation
GO:0072183 negative regulation of nephron tubule epithelial cell differentiation
GO:0072202 cell differentiation involved in metanephros development
GO:0072203 cell proliferation involved in metanephros development
GO:0072207 metanephric epithelium development
GO:0072210 metanephric nephron development
GO:0072215 regulation of metanephros development
GO:0072217 negative regulation of metanephros development
GO:0072234 metanephric nephron tubule development
GO:0072243 metanephric nephron epithelium development
GO:0072257 metanephric nephron tubule epithelial cell differentiation
GO:0072273 metanephric nephron morphogenesis
GO:0072283 metanephric renal vesicle morphogenesis
GO:0072307 regulation of metanephric nephron tubule epithelial cell differentiation
GO:0072308 negative regulation of metanephric nephron tubule epithelial cell differentiation
GO:0090077 foam cell differentiation
GO:0090183 regulation of kidney development
GO:0090185 negative regulation of kidney development
GO:0097696 STAT cascade
GO:0098542 defense response to other organism
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1902532 negative regulation of intracellular signal transduction
GO:1905330 regulation of morphogenesis of an epithelium
GO:1905331 negative regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
GO:2000181 negative regulation of blood vessel morphogenesis
GO:2000696 regulation of epithelial cell differentiation involved in kidney development
GO:2000697 negative regulation of epithelial cell differentiation involved in kidney development
GO:2001012 mesenchymal cell differentiation involved in renal system development
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000983 transcription factor activity, RNA polymerase II core promoter sequence-specific
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001159 core promoter proximal region DNA binding
GO:0001664 G-protein coupled receptor binding
GO:0005126 cytokine receptor binding
GO:0005164 tumor necrosis factor receptor binding
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0031730 CCR5 chemokine receptor binding
GO:0032813 tumor necrosis factor receptor superfamily binding
GO:0035257 nuclear hormone receptor binding
GO:0042379 chemokine receptor binding
GO:0045296 cadherin binding
GO:0048020 CCR chemokine receptor binding
GO:0050839 cell adhesion molecule binding
GO:0051427 hormone receptor binding
GO:0051721 protein phosphatase 2A binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0005913 cell-cell adherens junction
GO:0030424 axon
GO:0030425 dendrite
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG hsa04062 Chemokine signaling pathway
hsa04380 Osteoclast differentiation
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04917 Prolactin signaling pathway
hsa04919 Thyroid hormone signaling pathway
Reactome R-HSA-1169410: Antiviral mechanism by IFN-stimulated genes
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1839124: FGFR1 mutant receptor activation
R-HSA-982772: Growth hormone receptor signaling
R-HSA-1169408: ISG15 antiviral mechanism
R-HSA-168256: Immune System
R-HSA-913531: Interferon Signaling
R-HSA-909733: Interferon alpha/beta signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-6783589: Interleukin-6 family signaling
R-HSA-1059683: Interleukin-6 signaling
R-HSA-912694: Regulation of IFNA signaling
R-HSA-877312: Regulation of IFNG signaling
R-HSA-162582: Signal Transduction
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5655302: Signaling by FGFR1 in disease
R-HSA-449147: Signaling by Interleukins
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-1839117: Signaling by cytosolic FGFR1 fusion mutants
Summary
SymbolSTAT1
Namesignal transducer and activator of transcription 1, 91kDa
Aliases STAT91; transcription factor ISGF-3 components p91/p84; signal transducer and activator of transcription 1, ......
Chromosomal Location2q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between STAT1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between STAT1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28276425Breast CarcinomaPromote immunityHerein we show that the ShcA pathway simultaneously activates STAT3 immunosuppressive signals and impairs STAT1-driven immune surveillance in breast cancer cells. Impaired Y239/Y240-ShcA phosphorylation selectively reduces STAT3 activation in breast tumours, profoundly sensitizing them to immune checkpoint inhibitors and tumour vaccines. Finally, the ability of diminished tyrosine kinase signalling to initiate STAT1-driven immune surveillance can be overcome by compensatory STAT3 hyperactivation in breast tumours.
26676749Head and Neck Squamous Cell CarcinomaInhibit immunity (T cell function)Interferon gamma (IFNγ) and the epidermal growth factor receptor (EGFR) utilize Janus kinase 2 (JAK2) as a common signaling node to transmit tumor cell-mediated extrinsic or intrinsic signals, respectively. Collectively, our findings suggest a novel role for JAK2/STAT1 in EGFR-mediated immune evasion, and therapies targeting this signaling axis may be beneficial to block PD-L1 upregulation found in a large subset of HNC tumors.
26404003Lung CacinomaPromote immunity (infiltration)Systemic DLL-1 administration increased T-cell infiltration into tumors and elevated numbers of CD44(+)CD62L(+)CD8(+) memory T cells while decreasing the number of regulatory T cells and limiting tumor vascularization. This treatment was associated with upregulation of Notch and its ligands in tumor-infiltrating T cells enhanced expression of T-bet and phosphorylation of Stat1/2.
25972070Head and Neck Squamous Cell CarcinomaPromote immunityEGFR induces HLA downregulation through SHP-2/STAT1 suppression. Abrogating EGFR-induced immune escape mechanisms and restoring STAT1 signaling to reverse HLA downregulation using cetuximab should be combined with strategies to enhance adaptive cellular immunity.
25480946Head and Neck Squamous Cell CarcinomaPromote immunity (T cell function)SHP-2 activation by fusaruside suppresses p-STAT1/T-bet and production of Th1 cytokines. Overall, these results defined a PD-1/SHP-2/STAT1/T-bet signaling axis mediating the suppressive effects of PD-1 on Th1 immunity at tumor sites. Our findings argue that PD-1 or SHP-2 blockade will be sufficient to restore robust Th1 immunity and T-cell activation and thereby reverse immunosuppression in the tumor microenvironment.
28783722MelanomaPromote immunity (T cell function); essential for immunotherapyLoss of expression of these 19 genes within tumours could diminish or extinguish the presentation of tumour antigens (including HLA-A, HLA-F, B2M, TAP1 and TAP2); T cell co- stimulation (ICAM1, CLECL1, LILRA1 and LILRA3); or cytokine production and signalling (JAK2 and STAT1) in the tumour microenvironment that drive infiltration and activation of T cells, and thus serve as a principal mechanism in immune evasion.
28723893MelanomaPromote immunity; increase the efficacy of immunotherapyWe confirmed this finding in an in vivo competitive assay that compared the relative growth of mixtures of isogenic Stat1-null or control B16 cells in animals treated with immunotherapy (Fig. 1f). In wild-type mice treated with GVAX and anti-PD-1 immunotherapy, the relative proportion of Stat1-null cells increased significantly (Fig. 1g, h; P < 0.01, Student’s t-test), suggesting that Stat1-null cells have a marked growth advantage over wild-type tumour cells when under immune attack.
23486482Breast CarcinomaInhibit immunity (T cell function)Ectopic overexpression of constitutively active STAT1 in TM40D cells promoted mobilization of myeloid-derived suppressor cells (MDSCs) and inhibition of antitumor T cells, resulting in aggressive tumor growth in tumor-transplanted, immunocompetent mice.
29090321Hepatocellular CarcinomaInhibit immunity (T cell function)In the present study, we asked whether TNF-α can promote the expression of B7-H1 induced by IFN-γ in HCC cells. We found that JAK/STAT1/IRF1 was the primary pathway responsible for induction of B7-H1 expression by IFN-γ in human HCC cell lines. TNF-α and IFN-γ synergistically induced the expression of B7-H1 in the HCC cells. Moreover, the mechanism of the synergy was that TNF-α enhanced IFN-γ signaling by upregulating the expression of IFN-γ receptors.
29034543Gastric CarcinomaInhibit immunity (T cell function)PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Our in?vitro findings showed that interferon gamma upregulated programmed death ligand-1 expression on solid tumor cells through the JAK-signal transducer and activator of transcription pathway, and impaired the cytotoxicity of tumor antigen-specific CTL against tumor cells.
27470968Gastrointestinal Stromal TumorPromote immunityIn human GIST cell lines, treatment with imatinib abrogated the IFNγ-induced upregulation of PD-L1 via STAT1 inhibition.
17363736Multiple Myeloma-IgGInhibit immunity (T cell function)We observed that B7-H1 was expressed in most MM plasma cells, but not cells isolated from monoclonal gammopathy of undetermined significance or healthy donors. This expression was increased or induced by IFN-gamma and Toll-like receptor (TLR) ligands in isolated MM plasma cells. Blocking the MEK/ERK pathway inhibited IFN-gamma-mediated and TLR-mediated expression of B7-H1. Inhibition of the MyD88 and TRAF6 adaptor proteins of the TLR pathway blocked not only B7-H1 expression induced by TLR ligands but also that mediated by IFN-gamma. IFN-gamma-induced STAT1 activation, via MEK/ERK and MyD88/TRAF6, and inhibition of STAT1 reduced B7-H1 expression. MM plasma cells stimulated with IFN-gamma or TLR ligands inhibited cytotoxic T lymphocytes (CTLs) generation and this immunosuppressive effect was inhibited by preincubation with an anti-B7-H1 antibody, the UO126 MEK inhibitor, or by transfection of a dominant-negative mutant of MyD88.
24796276Breast CarcinomaInhibit immunityHere, we report that intense local proliferation of fully differentiated macrophages rather than low-pace recruitment of blood-borne precursors drives TAM accumulation in a mouse model of spontaneous mammary carcinogenesis, the MMTVneu strain. TAM differentiation and expansion is regulated by CSF1, whose expression is directly controlled by STAT1 at the gene promoter level. These findings appear to be also relevant for human breast cancer, in which an interrelationship between STAT1, CSF1, and macrophage marker expression was identified.
27923823Nasopharyngeal CarcinomaInhibit immunity; immunotherapy targetbortezomib, a proteasomal inhibitor, inhibited the pathways leading to STAT1 and IRF-1 activation, both of which are necessary for IDO expression.
23958683SarcomaPromote immunity (T cell function)Signal transducer and activator of transcription 1 (Stat1) mediates anti-viral responses and cytokine-driven anti-proliferative, apoptotic and immunomodulatory activities. Knockout of Stat1 enhanced the development of sarcomas induced by the chemical carcinogen 3-methylcholanthrene (MCA). Interestingly, restoration of Stat1 expression in Stat1?/? tumours resulted in diminished involvement of NK cells and increased contribution of CD8? T cells in anti-tumour responses.
23958683SarcomaInhibit immunity (NK cell function)Interestingly, restoration of Stat1 expression in Stat1?/? tumours resulted in diminished involvement of NK cells and increased contribution of CD8? T cells in anti-tumour responses.
23873689Ovarian CancinomaInhibit immunityIn vitro experiments and immunochemistry indicated that IL-27 is also involved in IL-18BP upregulation in EOC cell lines and primary cells through STAT1 activation.
23843024Breast CarcinomaPromote immunity (T cell function); essential for immunotherapyIn contrast, Stat1-deficient mice were resistant to tumor growth inhibition by lapatinib and/or doxorubicin and exhibited impaired T-cell activation and reduced T-cell infiltration of the tumor in response to drug treatment. Furthermore, Stat1-deficiency resulted in reduced expression of the T-cell chemotactic factors CXCL9, CXCL10, and CXCL11 in the tumor epithelium. Taken together, the results point to an important contribution toward enhancing T-cell and IFN-γ-based immunity by lapatinib as well as doxorubicin and emphasize the role of Stat1 in building an effective antitumor immune response.
27994058Thyroid Gland CarcinomaInhibit immunityMoreover, we found that, the STAT1-IRF1 pathway was instrumental for IDO1 expression in RET/PTC3 expressing cells. In detail, RET/PTC3 induced STAT1 overexpression and phosphorylation at Ser-727 and Tyr-701. STAT1 transcriptional regulation appeared to require activation of the canonical NF-κB pathway.
22805310Soft Tissue SarcomaInhibit immunity (uSTAT1); Promote immunity (pSTAT1)Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. RNAi-mediated silencing of STAT1 in STS cells was sufficient to increase expression of the apoptotic mediators Fas and Bad and to elevate the sensitivity of STS cells to Fas-mediated apoptosis. Together, our findings show how the phosphorylation status of pSTAT1 determines its function as a tumor suppressor, with uSTAT1 acting as a tumor promoter that acts by elevating resistance to Fas-mediated apoptosis to promote immune escape.
20581241Colorectal CarcinomaPromote immunityThere was a direct correlation between nSTAT1 expression and ITTC (p<0.001). Patients whose tumours had a high level of ITTC and nSTAT1 survived 20 months longer than those whose tumours had a low level of ITTC and no nSTAT1.
29702007Breast CarcinomaInhibit immunityDual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. We found that individual inhibition of STAT1 and STAT3 activation partially downregulated PD-L1, while combined inhibition completely downregulated PD-L1 expression.
23386060Breast Carcinoma; Cervical CarcinomaPromote immunitywe show that hCAF1/CNOT7 regulates class I and II IFN pathways at different crucial steps.Since abnormal and unbalanced JAK/STAT activation is associated with immune disorders and cancer, hCAF1 could play a major role in innate immunity and oncogenesis, contributing to tumour escape
23363816Head and Neck CarcinomaPromote immunityIn HNC cells, SHP2 depletion significantly upregulated expression of pSTAT1 and HLA class I APM components. Overexpression of SHP2 in nonmalignant keratinocytes inhibited IFN-gamma-mediated STAT1 phosphorylation, and SHP2 depletion in STAT1(-/-) tumor cells did not significantly induce IFN-gamma-mediated APM component expression, verifying STAT1 dependence of SHP2 activity
21964766MelanomaPromote immunityWhole genome transcriptional analysis clearly indicate that regression of melanoma metastases is due to an acute immune rejection mediated by the upregulation of genes involved in antigen presentation and interferon mediated response (STAT-1/IRF-1) in all the regressing metastases from both patients.
21796616MelanomaPromote immunityThe production of multiple cytokines (IFNgamma, TNFalpha, IL-2) and upregulation of LAMP-1 (CD107a) by tumor (Melan-A/MART-1) specific T-cells was comparable to virus (EBV-BMLF1) specific CD8 T-cells. Furthermore, phosphorylation of STAT1, STAT5 and ERK1/2, and expression of CD3 zeta chain were similar in tumor- and virus-specific T-cells, demonstrating functional signaling pathways.
21784871Breast CarcinomaPromote immunityFurthermore, we showed that treatment with these NPs resulted in priming of the immune TME, characterized by increased IFN-gamma, p-STAT-1, GM-CSF, IL-2, IL-15, and IL-12b and reduced TGF-beta, IL-6, and IL-10 protein expression. In addition, we found significantly increased tumor infiltration by activated CD8(+) T cells, M1 macrophages, and dendritic cells.
Summary
SymbolSTAT1
Namesignal transducer and activator of transcription 1, 91kDa
Aliases STAT91; transcription factor ISGF-3 components p91/p84; signal transducer and activator of transcription 1, ......
Chromosomal Location2q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of STAT1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 8.49; FDR: 0.000150 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: 2.44; FDR: 0.000381 Sensitive to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.78 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 8.89; FDR: 0.000 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 6.51; FDR: 0.000 Sensitive to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSTAT1
Namesignal transducer and activator of transcription 1, 91kDa
Aliases STAT91; transcription factor ISGF-3 components p91/p84; signal transducer and activator of transcription 1, ......
Chromosomal Location2q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of STAT1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0170.962
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1080.971
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1070.961
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5480.141
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5860.804
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5080.875
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3580.534
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6340.786
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0140.996
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4960.527
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0880.768
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3710.00374
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of STAT1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSTAT1
Namesignal transducer and activator of transcription 1, 91kDa
Aliases STAT91; transcription factor ISGF-3 components p91/p84; signal transducer and activator of transcription 1, ......
Chromosomal Location2q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STAT1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSTAT1
Namesignal transducer and activator of transcription 1, 91kDa
Aliases STAT91; transcription factor ISGF-3 components p91/p84; signal transducer and activator of transcription 1, ......
Chromosomal Location2q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STAT1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STAT1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSTAT1
Namesignal transducer and activator of transcription 1, 91kDa
Aliases STAT91; transcription factor ISGF-3 components p91/p84; signal transducer and activator of transcription 1, ......
Chromosomal Location2q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STAT1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSTAT1
Namesignal transducer and activator of transcription 1, 91kDa
Aliases STAT91; transcription factor ISGF-3 components p91/p84; signal transducer and activator of transcription 1, ......
Chromosomal Location2q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of STAT1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSTAT1
Namesignal transducer and activator of transcription 1, 91kDa
Aliases STAT91; transcription factor ISGF-3 components p91/p84; signal transducer and activator of transcription 1, ......
Chromosomal Location2q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between STAT1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSTAT1
Namesignal transducer and activator of transcription 1, 91kDa
Aliases STAT91; transcription factor ISGF-3 components p91/p84; signal transducer and activator of transcription 1, ......
Chromosomal Location2q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting STAT1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.